HONG KONG, March 14, 2011 /PRNewswire/ — OrbusNeich today
announced the launch of the CE marked Azule Cobalt Chromium Stent.
The Azule Stent combines the proven stent design of its
predecessor, the company’s Blazer™ Cobalt Chromium Stent,
with a delivery system with enhanced crossability and flexible
deliverability.
Azule features OrbusNeich’s unique Dual Helix stent design,
offering conformability and radial strength on thin, flexible and
low-profile cobalt chromium stent struts. The stent’s tip
length has been reduced from 5 mm to 4.25 mm, improving
deliverability and crossability. The precise laser forming of
the tip results in a lower lesion entry profile, and the controlled
laser welding of the balloon to the catheter improves the stent’s
trackability and flexibility.
“Continuous technology advancement is mandated by our customers
and the very nature of interventional cardiology,” said Al Novak,
OrbusNeich’s Chairman and CEO. “We believe the underlying
deliverability of a stent is, and will continue to be, a critically
important factor that we strive to improve.”
About OrbusNeich
OrbusNeich is a global company that designs, develops,
manufactures and markets innovative medical devices for the
treatment of vascular diseases. Current products are the world’s
first pro-healing stent, the Genous™ Stent, as well as other
stents and balloons marketed under the names of Azule, R stent,
Scoreflex™, Sapphire™, Sapphire II and Sapphire NC.
Development stage products include the Combo™ Bio-engineered
Sirolimus Eluting Stent, or Combo Stent, which combines the Genous
pro-healing technology for rapid endothelial coverage with an
abluminal sirolimus drug elution for the control of neointimal
proliferation. OrbusNeich is headquartered in Hong Kong and has
operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken,
The Netherlands; and Tokyo, Japan. OrbusNeich, which has
provided
‘/>”/>
